检测多西他赛血药浓度指导晚期非小细胞#br#
肺癌患者的个体化治疗#br#

	#br#

摘要/Abstract

摘要： 目的观察多西他赛（DTX）治疗晚期非小细胞肺癌（NSCLC）根据血药浓度调整剂量对疗效及不良反应的影响。
方法收集2015年10月至2017年4月晚期NSCLC患者100例，一线予以DTX联合卡铂方案化疗。第1周期DTX剂量为75 mg／m2，后根据所得的血浆浓度与时间曲线下面积（AUC）及是否存在骨髓抑制进行分组。AUC在25～37 mg·h／L的患者分入常规组；＜25 mg·h／L或＞37 mg·h／L且存在骨髓抑制者分入试验组。常规组DTX剂量在后续周期中均按75 mg／m2给予。试验组后续周期中DTX剂量需根据上一周期AUC水平及骨髓抑制的程度在上周期DTX剂量基础上进行调整。
结果常规组（n=50）获 PR 16例，SD 21例，PD 13例；有效率（RR）为320％，疾病控制率（DCR）为740％；中位无进展生存时间（PFS）为55个月。试验组（n=50）获PR 19例，SD18例，PD13例；RR为380％，DCR为740％；中位PFS为58个月。两组RR、DCR和中位PFS的差异均无统计学意义（P＞005）。常规组4个周期AUC的均值差异较小，波动于31～33（mg·h／L），仅2例患者第4周期因骨髓抑制DTX减量25％。试验组第2周期35例患者DTX减量15％，8例患者减量25％，7例患者减量30％；第3周期5例患者减量15％，1例患者减量25％。随着DTX剂量的调整，AUC均值也随之减低，第4周期AUC均值低于常规组（30 mg·h/L vs. 33 mg·h/L， P＜005）。常规组骨髓抑制的比例随着化疗周期数的增加而增高，而试验组骨髓抑制的比例随着化疗周期数的增加及AUC值的降低而减低，第4周期试验组骨髓抑制的发生率远低于常规组（162％ vs. 649％，P＜0001）。
结论通过血药浓度调整DTX剂量治疗NSCLC，疗效与常规给药方法相当，不良反应减轻，值得临床推广应用。

关键词: 非小细胞肺癌, 多西他赛, 血药浓度, 化学治疗

Abstract: ObjectiveTo explore the changes in the efficacy and adverse events of docetaxel （DTX） after adjusting dose according to the plasma concentration in advanced nonsmall cell lung cancer（NSCLC）.
MethodsA total of 100 advanced NSCLC patients from October 2015 to April 2017 were enrolled and given DTX+carboplatin regimen as the firstline chemotherapy. The dose of DTX for the first cycle was 75 mg／m2， and then patients were divided into conventional group and experimental group according to area under the plasma drug concentrationstime curve （AUC） and the degree of myelosuppression. Patients of AUC ranging from 25 to 37 mg·h／L were assigned into conventional group， and patients of AUC ＜25 or ＞37 mg·h／L and myelosuppression were assigned to experimental group. The DTX dose in conventional group was given at 75 mg／m2 in subsequent cycles. And the dose in experimental group was adjusted according to the AUC and the degree of myelosuppression in the previous cycle.
ResultsIn conventional group， there were 16 cases in PR， 21 cases in SD， and 13 cases in PD. The response rate （RR） was 320％， the disease control rate was 740％， and the median progressionfree survival（PFS） was 55 months. In experimental group， there were 19 cases in PR， 18 cases in SD， and 13 cases in PD. The RR and DCR were 380％ and 740％， and the median PFS was 58 months. The differences of RR， DCR and median PFS between the two groups had no differences （P＞005）. The average AUC ranged 3133（mg·h／L） in conventional group. The dose of DTX was reduced by 25％ due to myelosuppression in 2 patients at the fourth cycle. In experimental group， 35 patients had 15％ DTX dose reduction， 8 patients had 20％ reduction and 7 patients had 30％ reduction at the second cycle； 5 patients had 15％ reduction and 1 patient had 25％ reduction at the third cycle. With the adjustment of DTX， the average of AUC decreased. The average AUC at the fourth cycle was 30， lower than 33 of conventional group （P＜005）. The occurrence of myelosuppression in conventional group rose with the increase of chemotherapy cycles， while that in experimental group decreased with the increase of chemotherapy cycles and decrease of AUC. The occurrence of myelosuppression in experimental group was 162％， much lower than 649％ of conventional group （P＜0001）.
ConclusionBy adjusting the DTX dose based on plasma concentration for NSCLC， the efficacy is equal to conventional treatment with less adverse events， which is worthy of clinical application.

Key words: Nonsmall cell lung cancer （NSCLC）, Docetaxel, Plasma concentration, Chemotherapy

蒋侃, 黄诚, 林根, 吴标, 郑晓彬, 陈胜佳. 检测多西他赛血药浓度指导晚期非小细胞#br# 肺癌患者的个体化治疗#br#

#br#

[J]. 临床肿瘤学杂志, 2018, 23(7): 610-614.

JIANG Kan, HUANG Cheng, LIN Gen, WU Biao, ZHENG Xiaobin, CHEN Shengjia. . Individualization treatment of docetaxel by detecting plasma concentration in advanced nonsmall cell lung cancer#br#[J]. Chinese Clinical Oncology, 2018, 23(7): 610-614.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	刘锦；李贵新；马传香. 恶性黑色素瘤腹腔转移１例[J]. 临床肿瘤学杂志, 2009, 14(1): 96 .
[2]	石　玮¹，华海清²，王兴华¹. 放疗对肠屏障功能的影响及研究进展[J]. 临床肿瘤学杂志, 2009, 14(1): 89 .
[3]	王杰军，李　睿. ＮＣＣＮ成人癌痛临床实践指南解读[J]. 临床肿瘤学杂志, 2009, 14(1): 80 .
[4]	崔传亮，迟志宏，袁香庆，斯　璐，盛锡楠，郭　军. 重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 74 .
[5]	高亚杰¹，关小倩¹，杨海林¹，张　阳²，欧阳学农³，杨建伟⁴，陈　焰⁵,徐建明⁶，赵宣良⁷，王宝成⁸，刘文超⁹，张贺龙¹⁰，南克俊¹¹，王湘辉¹² . 注射用左亚叶酸钙联合治疗晚期胃癌和结直肠癌的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 47 .
[6]	白秀丽¹，马振刚¹，李际君². 紫杉醇联合卡培他滨治疗进展期胃癌的临床观察[J]. 临床肿瘤学杂志, 2009, 14(1): 68 .
[7]	徐卫国¹，杨小青²，郝世柱¹，宋纪宁¹，张鹏东¹，胡潺潺¹，王文雅¹. 大肠癌组织中Ｎｅｕｒｏｐｉｌｉｎ-１的表达及其与肿瘤血管生成的相关性研究[J]. 临床肿瘤学杂志, 2009, 14(1): 29 .
[8]	许景艳¹，欧阳建^１，章宜芬²，周荣富¹，陈　兵¹，张启国¹，杨永公¹，邵小雁¹，徐　勇¹，关朝阳¹. 原发性肋骨血管肉瘤的诊治探讨[J]. 临床肿瘤学杂志, 2009, 14(1): 70 .
[9]	徐晓明¹，唐金海¹，刘万花²，郑凯尔²，秦建伟¹，赵祥生¹，张　彤³. 触诊阴性乳腺癌的定位方法与同期手术治疗[J]. 临床肿瘤学杂志, 2009, 14(1): 43 .
[10]	张艳玲，邹　岚，肖　红，黄海辉，谭崇富，阮志华，王　希，梁后杰，庞学利. 影像引导调强放射治疗鼻咽癌[J]. 临床肿瘤学杂志, 2009, 14(1): 51 .